Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity
- PMID: 38723634
- DOI: 10.1016/j.stem.2024.04.012
Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity
Erratum in
-
Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity.Cell Stem Cell. 2025 May 1;32(5):854-856. doi: 10.1016/j.stem.2025.03.013. Epub 2025 Apr 11. Cell Stem Cell. 2025. PMID: 40215983 No abstract available.
Abstract
Generation of chimeric antigen receptor macrophages (CAR-Ms) from human pluripotent stem cells (hPSCs) offers new prospects for cancer immunotherapy but is currently challenged by low differentiation efficiency and limited function. Here, we develop a highly efficient monolayer-based system that can produce around 6,000 macrophages from a single hPSC within 3 weeks. Based on CAR structure screening, we generate hPSC-CAR-Ms with stable CAR expression and potent tumoricidal activity in vitro. To overcome the loss of tumoricidal activity of hPSC-CAR-Ms in vivo, we use interferon-γ and monophosphoryl lipid A to activate an innate immune response that repolarizes the hPSC-CAR-Ms to tumoricidal macrophages. Moreover, through combined activation of T cells by hPSC-CAR-Ms, we demonstrate that activating a collaborative innate-adaptive immune response can further enhance the anti-tumor effect of hPSC-CAR-Ms in vivo. Collectively, our study provides feasible methodologies that significantly improve the production and function of hPSC-CAR-Ms to support their translation into clinical applications.
Keywords: human pluripotent stem cells; immunotherapy; innate-adaptive immune; macrophages.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
